Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-12-19 16:11:41
Reporting Period:
Accepted Time:
2018-12-19 16:11:41
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1643756 G. John Aunins C/o Seres Therapeutics, Inc.
200 Sidney Street
Cambridge MA 02139
Chief Technology Officer & Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-12-17 14,282 $6.39 75,250 No 4 S Direct
Common Stock Acquisiton 2018-12-19 10,000 $0.00 85,250 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock RESTRICTED STOCK UNITS Disposition 2018-12-19 10,000 $0.00 10,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.2100 to $6.5900. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Each restricted stock unit represents right to receive one share of Issuer common stock.
  4. These restricted stock units have vested and settled as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018.